# Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

> **NCT03507998** · PHASE1 · UNKNOWN · sponsor: **Curegenix Inc.** · enrollment: 39 (estimated)

## Conditions studied

- Colorectal Adenocarcinoma
- Gastric Adenocarcinoma
- Pancreatic Adenocarcinoma
- Bile Duct Carcinoma
- Hepatocellular Carcinoma
- Esophageal Carcinoma
- Gastrointestinal Cancer

## Interventions

- **DRUG:** CGX1321

## Key facts

- **NCT ID:** NCT03507998
- **Lead sponsor:** Curegenix Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06-17
- **Primary completion:** 2021-04-01
- **Final completion:** 2021-04-01
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2020-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03507998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03507998, "Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03507998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*